By now it is widely accepted that PRMT5 exerts oncogene-like activities and its elevation is highly correlated with unfavorable outcomes in patients with lung cancer 8, breast cancer 9, gastric cancer 10, ovarian cancer 11, prostate cancer 12 and glioblastoma 13. This evidence concerns the gene PRMT5 and gastric cancer.